Made byBobr AI

Carbocisteine for COPD Exacerbation: Meta-Analysis & Safety

Explore a systematic review and meta-analysis on Carbocisteine (1500 mg/day) effectiveness in reducing COPD exacerbation rates based on global RCT evidence.

#copd#carbocisteine#systematic-review#meta-analysis#pulmonology#respiratory-health#medical-research#rct
Watch
Pitch

Carbocisteine in COPD Management: A Systematic Review and Meta-Analysis

Evidence from Randomized Controlled Trials on Exacerbation Reduction and Safety Profile

Advances in Respiratory Medicine 2026, 94, 2
DOI: https://doi.org/10.3390/arm94010002
Made byBobr AI

Background & Rationale

Global Health Burden

COPD is a major global respiratory disease characterized by excessive mucus, airway obstruction, and recurrent exacerbations.

Acute Exacerbations

Acute exacerbations are the leading driver of COPD morbidity, hospitalization rates, and overall mortality.

Role of Carbocisteine

Carbocisteine (1500 mg/day) serves as a mucoactive agent with notable mucoregulatory, antioxidant, and anti-inflammatory properties.

Evidence Gap Identified

Despite its widespread use, high-quality pooled evidence from RCTs was lacking — prompting this systematic review and meta-analysis.

Made byBobr AI
Materials & Methods

Search Strategy & Study Selection

Literature Search Strategy

Search Terms
"carbocisteine", "COPD", "exacerbation*", "randomized controlled trial"

Search Terms
'carbocisteine'/exp OR carbocisteine AND 'chronic obstructive lung disease'

Search Terms
[carbocisteine OR carboxymethylcysteine] AND COPD in Title/Abstract

Search Terms
Condition: COPD | Intervention: Carbocisteine

Note: Search period: inception to latest available date. Boolean operators applied across all databases.

Study Selection Process

65 records identified
(database + manual screening)
31 articles
(after removing 34 duplicates)
Full-text articles assessed
4 studies included
(n = 1,746 patients)

Inclusion Criteria

  • RCTs only • Double-blind, placebo-controlled
  • Carbocisteine 1500 mg/day
  • ≥6 months follow-up
  • COPD/chronic bronchitis (spirometry-confirmed)
Made byBobr AI
Materials & Methods

Data Extraction, Risk of Bias & Statistical Analysis

Inclusion & Exclusion Criteria

Inclusion

  • ✓ RCTs, double-blind, placebo-controlled
  • ✓ Carbocisteine 1500 mg/day vs. placebo
  • ✓ COPD/chronic bronchitis (FEV1/FVC <0.70 or FEV1 40–79% predicted)
  • ✓ ≥6 months follow-up
  • ✓ Outcomes: exacerbation rate or adverse events

Exclusion

  • ✗ No placebo control
  • ✗ Observational, case reports, non-RCTs
  • ✗ No relevant outcome data

Data Extraction & Risk of Bias

Data Extraction

  • • Two independent reviewers (CSK & SSH)
  • • Standardized extraction form
  • • Study location, design, duration, sample size, mean age
  • • Exacerbation rates (mean/year) & adverse events

Risk of Bias

RoB 2 Assessment Tool
5 Domains Assessed:
Randomization process · Deviation from interventions · Missing outcome data · Outcome measurement · Reporting selection
ALL 4 TRIALS: LOW RISK

Statistical Analysis

Software: MetaXL v5.3 (EpiGear International)
  • • Exacerbation rates: Weighted Mean Difference (WMD) with 95% CI
  • • Adverse events: Pooled Odds Ratio (OR), Mantel–Haenszel method
  • • Model: Random-effects (both outcomes)
  • • Heterogeneity:
    Cochran's Q test (p<0.10 = sig)
    + I² statistic (>50% = substantial)
  • • Rationale for random-effects: variability in populations, durations, baseline rates, geography

*Study selection and data extraction performed independently; disagreements resolved by consensus (third reviewer KT if needed).

Made byBobr AI

Materials & Methods

Literature Search

  • Databases: PubMed, Embase, Cochrane Library, ClinicalTrials.gov
  • Keywords: "carbocisteine", "COPD", "exacerbations", "randomized controlled trial"
  • Date: Inception to latest available date
  • Manual reference screening also performed

Inclusion Criteria

  • Randomized, double-blind, placebo-controlled trials
  • Patients: COPD / chronic obstructive bronchitis (FEV1/FVC < 0.70 or FEV1 40–79%)
  • Intervention: Carbocisteine 1500 mg/day vs placebo
  • Outcomes: Exacerbation rate and adverse events
  • Minimum follow-up: 6 months
Risk of Bias: Cochrane RoB2 tool — 5 domains assessed; all 4 trials rated LOW RISK overall
Statistical Method: Weighted Mean Difference (WMD) with 95% CI (random-effects model) for exacerbations; Odds Ratio (OR) with Mantel-Haenszel for adverse events.
Made byBobr AI

Study Selection & Included Trials

65
Records Identified
➔
34
Duplicates Removed
➔
31
Screened
➔
4
Included Trials
(1746 patients)
Study Location Duration Carbocisteine Dose N (Treatment/Control) Mean Age Exacerbation Rate
(Carbocisteine vs Placebo)
Allegra et al. (1996) Italy 6 months 1500 mg/day 171 / 181 60.0 yrs 0.92 vs 1.48
Yasuda et al. (2006) Japan 12 months 1500 mg/day 78 / 78 72.7 yrs 0.54 vs 1.38
Zheng et al. (2008) China 12 months 1500 mg/day 353 / 354 65.2 yrs 1.01 vs 1.35
Zhou et al. (2025) China 12 months 1500 mg/day 356 / 175 64.0 yrs 0.39 vs 0.46
i
All 4 trials were randomized, double-blinded, placebo-controlled. All rated LOW risk of bias (Cochrane RoB2).
Made byBobr AI

Meta-Analysis Results: Exacerbation Rates

Study
← Favors Carbocisteine
Favors Placebo →
WMD (95% CI)
Weight
-1.5
-1.0
-0.5
0.0
0.5
Allegra et al. (1996)
−0.56 (−0.87, −0.25)
23.0%
Yasuda et al. (2006)
−0.84 (−1.29, −0.39)
17.9%
Zheng et al. (2008)
−0.34 (−0.51, −0.17)
28.1%
Zhou et al. (2025)
−0.07 (−0.08, −0.06)
31.0%
Overall
−0.40 (−0.69, −0.11)
Heterogeneity: Q=31.13, p=0.00, I²=90%
Carbocisteine significantly reduced annual COPD exacerbation rate vs placebo
— WMD = −0.40 (95% CI: −0.69 to −0.11)
Advances in Respiratory Medicine 2026, 94, 2
DOI: https://doi.org/10.3390/arm94010002
Made byBobr AI

Safety Profile: Adverse Events Analysis

OR = 1.02 (95% CI: 0.76–1.37)
No significant difference in adverse events
I² = 0% — No heterogeneity

Adverse Event Rates by Trial

Carbocisteine
Placebo
Allegra
3.5%
6.1%
Zheng
16.2%
15.8%
Zhou
18.0%
15.8%
Yasuda
Data not available (N/A)

Types of Adverse Events

Gastrointestinal
Dyspepsia, nausea, diarrhoea, abdominal discomfort
Respiratory
Sore throat, cough, rhinorrhoea, cold-like symptoms
Other
Headache, dizziness, minor skin reactions
Serious Events
Uncommon, unrelated to treatment
No hepatotoxicity, nephrotoxicity or cardiovascular complications identified

Conclusion: Carbocisteine is well-tolerated in COPD populations with an adverse-event profile comparable to placebo over 6–12 months of therapy.

Made byBobr AI
Bobr AI

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT

Create your own professional slide deck with real images, data charts, and unique design in under a minute.

Generate For Free

Carbocisteine for COPD Exacerbation: Meta-Analysis & Safety

Explore a systematic review and meta-analysis on Carbocisteine (1500 mg/day) effectiveness in reducing COPD exacerbation rates based on global RCT evidence.

Carbocisteine in COPD Management: A Systematic Review and Meta-Analysis

Evidence from Randomized Controlled Trials on Exacerbation Reduction and Safety Profile

Advances in Respiratory Medicine 2026, 94, 2

DOI: https://doi.org/10.3390/arm94010002

Background & Rationale

COPD is a major global respiratory disease characterized by excessive mucus, airway obstruction, and recurrent exacerbations.

Acute exacerbations are the leading driver of COPD morbidity, hospitalization rates, and overall mortality.

Carbocisteine (1500 mg/day) serves as a mucoactive agent with notable mucoregulatory, antioxidant, and anti-inflammatory properties.

Despite its widespread use, high-quality pooled evidence from RCTs was lacking — prompting this systematic review and meta-analysis.

Materials & Methods

Search Strategy & Study Selection

Literature Search Strategy

Study Selection Process

Search period: inception to latest available date. Boolean operators applied across all databases.

Materials & Methods

Data Extraction, Risk of Bias & Statistical Analysis

Inclusion & Exclusion Criteria

Data Extraction & Risk of Bias

Statistical Analysis

*Study selection and data extraction performed independently; disagreements resolved by consensus (third reviewer KT if needed).

Materials & Methods

Literature Search

Databases:

PubMed, Embase, Cochrane Library, ClinicalTrials.gov

Keywords:

"carbocisteine", "COPD", "exacerbations", "randomized controlled trial"

Date:

Inception to latest available date

Manual reference screening also performed

Inclusion Criteria

Randomized, double-blind, placebo-controlled trials

Patients:

COPD / chronic obstructive bronchitis (FEV1/FVC &lt; 0.70 or FEV1 40–79%)

Intervention:

Carbocisteine 1500 mg/day vs placebo

Outcomes:

Exacerbation rate and adverse events

Minimum follow-up:

6 months

Risk of Bias:

Cochrane RoB2 tool — 5 domains assessed; all 4 trials rated LOW RISK overall

Statistical Method:

Weighted Mean Difference (WMD) with 95% CI (random-effects model) for exacerbations; Odds Ratio (OR) with Mantel-Haenszel for adverse events.

Study Selection & Included Trials

Meta-Analysis Results: Exacerbation Rates

Allegra et al. (1996)

−0.56 (−0.87, −0.25)

23.0%

Yasuda et al. (2006)

−0.84 (−1.29, −0.39)

17.9%

Zheng et al. (2008)

−0.34 (−0.51, −0.17)

28.1%

Zhou et al. (2025)

−0.07 (−0.08, −0.06)

31.0%

Overall

−0.40 (−0.69, −0.11)

Heterogeneity: Q=31.13, p=0.00, I²=90%

Carbocisteine significantly reduced annual COPD exacerbation rate vs placebo

— WMD = −0.40 (95% CI: −0.69 to −0.11)

Advances in Respiratory Medicine 2026, 94, 2

DOI: https://doi.org/10.3390/arm94010002

Safety Profile: Adverse Events Analysis

OR = 1.02 (95% CI: 0.76–1.37)

No significant difference in adverse events

I² = 0% — No heterogeneity

Carbocisteine is well-tolerated in COPD populations with an adverse-event profile comparable to placebo over 6–12 months of therapy.

  • copd
  • carbocisteine
  • systematic-review
  • meta-analysis
  • pulmonology
  • respiratory-health
  • medical-research
  • rct